.Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L04A_Immunosuppressants.L04AX09_DiroximelFumarate.DiroximelFumarate .Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L04A_Immunosuppressants.L04AX09_DiroximelFumarate.DiroximelFumarate| name: | DiroximelFumarate | |
| ATC code: | L04AX09 | route: | oral |
| compartments: | 1 | |
| dosage: | 231 | mg |
| volume of distribution: | 72 | L |
| clearance: | 38 | L/h |
| other parameters in model implementation | ||
Diroximel fumarate is an oral immunomodulatory drug used for the treatment of relapsing forms of multiple sclerosis (MS). It is a prodrug that is rapidly converted to monomethyl fumarate (MMF), the active metabolite which exerts anti-inflammatory and neuroprotective effects. It is an FDA- and EMA-approved medication as of 2019 and is currently in clinical use.
Pharmacokinetic parameters for healthy adult volunteers (fasted/fed), reporting on monomethyl fumarate (active metabolite) following 231 mg diroximel fumarate twice daily oral administration.
Kuchimanchi, M, et al., & Penner, N (2022). Development of a Population Pharmacokinetic Model for the Diroximel Fumarate Metabolites Monomethyl Fumarate and 2-Hydroxyethyl Succinimide Following Oral Administration of Diroximel Fumarate in Healthy Participants and Patients with Multiple Sclerosis. Neurology and therapy 11(1) 353–371. DOI:10.1007/s40120-021-00316-6 PUBMED:https://pubmed.ncbi.nlm.nih.gov/35041178